Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of DS-8500a in Japanese Patients with Type 2 Diabetes
NCT02222350Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of firuglipel in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in 24-hour weighted mean glucose at Day 28. Started Jul 2014; status: completed.
02
Drugs
firuglipel
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02222350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02222350.